Chukwuma A. Agu

Chukwuma A. Agu

Auto-generated profile, based on publicly available information

Chukwuma A. Agu

Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK 1

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2019 in Nature
Verified
Journal Article
Closed access
PDF file
RWReiner A. Wimmer
Reiner A. Wimmer
ALAlexandra Leopoldi
Alexandra Leopoldi
MAMartin Aichinger
Martin Aichinger
NWNikolaus Wick
Nikolaus Wick
BHBrigitte Hantusch
Brigitte Hantusch
JPJosef M Penninger
Josef M Penninger

10 May 2017 in Nature
Verified
Journal Article
Open access
PDF file
HKHelena Kilpinen
Helena Kilpinen
AGAngela Goncalves
Angela Goncalves
ALAndreas Leha
Andreas Leha
VAVackar Afzal
Vackar Afzal
KAKaur Alasoo
Kaur Alasoo
DGDaniel J. Gaffney
Daniel J. Gaffney
Technology utilizing human induced pluripotent stem cells (iPS cells) has enormous potential to provide improved cellular models of human disease. However, variable genetic and phenotypic characterization of many existing iPS cell lines limits their potential use for research and therapy. Here we describe the systematic generation, genotyping and phenotyping of 711 iPS cell lines derived from 301 healthy individuals by the Human Induced Pluripotent Stem Cells Initiative. Our study outlines the major sources of genetic and phenotypic variation in iPS cells and establishes their suitability as models of complex human traits and cancer. Through genome-wide profiling we find that 5–46% of the variation in different iPS cell phenotypes, including differentiation capacity and cellular morphology, arises from differences between individuals. Additionally, we assess the phenotypic consequences of genomic copy-number alterations that are repeatedly observed in iPS cells. In addition, we present a comprehensive map of common regulatory variants affecting the transcriptome of human pluripotent cells.

1 July 2013 in Cell
Verified
Journal Article
Open access
JWJacqueline K. White
Jacqueline K. White
AGAnna-Karin Gerdin
Anna-Karin Gerdin
NKNatasha A. Karp
Natasha A. Karp
EREd Ryder
Ed Ryder
MBMarija Buljan
Marija Buljan
BYBinnaz Yalcin
Binnaz Yalcin
Mutations in whole organisms are powerful ways of interrogating gene function in a realistic context. We describe a program, the Sanger Institute Mouse Genetics Project, that provides a step toward the aim of knocking out all genes and screening each line for a broad range of traits. We found that hitherto unpublished genes were as likely to reveal phenotypes as known genes, suggesting that novel genes represent a rich resource for investigating the molecular basis of disease. We found many unexpected phenotypes detected only because we screened for them, emphasizing the value of screening all mutants for a wide range of traits. Haploinsufficiency and pleiotropy were both surprisingly common. Forty-two percent of genes were essential for viability, and these were less likely to have a paralog and more likely to contribute to a protein complex than other genes. Phenotypic data and more than 900 mutants are openly available for further analysis. PAPERCLIP:

10 February 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
ACAnna S. E. Cuomo
Anna S. E. Cuomo
DSDaniel D. Seaton
Daniel D. Seaton
DMDavis J. McCarthy
Davis J. McCarthy
IMIker Martinez
Iker Martinez
MBMarc Jan Bonder
Marc Jan Bonder
OSOliver Stegle
Oliver Stegle
Recent developments in stem cell biology have enabled the study of cell fate decisions in early human development that are impossible to study in vivo. However, understanding how development varies across individuals and, in particular, the influence of common genetic variants during this process has not been characterised. Here, we exploit human iPS cell lines from 125 donors, a pooled experimental design, and single-cell RNA-sequencing to study population variation of endoderm differentiation. We identify molecular markers that are predictive of differentiation efficiency of individual lines, and utilise heterogeneity in the genetic background across individuals to map hundreds of expression quantitative trait loci that influence expression dynamically during differentiation and across cellular contexts.

27 September 2017 in Nature
Verified
Journal Article
Closed access
PDF file
UEUlrich Elling
Ulrich Elling
RWReiner A. Wimmer
Reiner A. Wimmer
ALAndreas Leibbrandt
Andreas Leibbrandt
TBThomas Burkard
Thomas Burkard
GMGeorg Michlits
Georg Michlits
JPJosef M Penninger
Josef M Penninger

5 December 2019 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SMSubhankar Mukhopadhyay
Subhankar Mukhopadhyay
EHEva Heinz
Eva Heinz
IPImmacolata Porreca
Immacolata Porreca
KAKaur Alasoo
Kaur Alasoo
AYAmy Yeung
Amy Yeung
FPFiona Powrie
Fiona Powrie
Loss of IL-10 signaling in macrophages (Mφs) leads to inflammatory bowel disease (IBD). Induced pluripotent stem cells (iPSCs) were generated from an infantile-onset IBD patient lacking a functional IL10RB gene. Mφs differentiated from IL-10RB−/− iPSCs lacked IL-10RB mRNA expression, were unable to phosphorylate STAT3, and failed to reduce LPS induced inflammatory cytokines in the presence of exogenous IL-10. IL-10RB−/− Mφs exhibited a striking defect in their ability to kill Salmonella enterica serovar Typhimurium, which was rescuable after experimentally introducing functional copies of the IL10RB gene. Genes involved in synthesis and receptor pathways for eicosanoid prostaglandin E2 (PGE2) were more highly induced in IL-10RB−/− Mφs, and these Mφs produced higher amounts of PGE2 after LPS stimulation compared with controls. Furthermore, pharmacological inhibition of PGE2 synthesis and PGE2 receptor blockade enhanced bacterial killing in Mφs. These results identify a regulatory interaction between IL-10 and PGE2, dysregulation of which may drive aberrant Mφ activation and impaired host defense contributing to IBD pathogenesis.